Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izae152 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Federico Argüelles-Arias und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Virgen Macarena University Hospital, Seville, Spain. Hauptthemen laut MEDLINE: Ustekinumab, Maintenance Chemotherapy, Crohn Disease, Colitis, Ulcerative. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
Ustekinumab (UST) is commonly used to treat Crohn’s disease and ulcerative colitis. However, some patients may experience diminishing response or require increased dosage. Intravenous (IV) UST maintenance is explored as a solution.
Objectives
We sought to evaluate IV UST maintenance effectiveness and safety in inflammatory bowel disease patients with partial or lost subcutaneous UST response.
Methods
This was a multicenter retrospective study of inflammatory bowel disease patients on IV UST maintenance. Clinical response and remission at weeks 12 and 52, defined as Harvey-Bradshaw Index ≤4 for Crohn’s disease or partial Mayo score ≤2 for ulcerative colitis. Objective markers reduction (fecal calprotectin, C-reactive protein), UST trough levels pre- and post-IV maintenance, and adverse events were assessed.
Results
A total of 59 patients were included. Clinical remission at weeks 12 and 52 achieved by 47.5% and 64.3% respectively. 96.6% continued IV UST at follow-up. UST serum levels quadrupled. No adverse events reported.
Conclusions
IV UST maintenance effectively sustained remission in most patients at 52 weeks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Department, Virgen Macarena University Hospital, Seville, Spain.
- Department of Medicine, University of Seville, Seville, Spain.
- Gastroenterology Department, Virgen de la Victoria University Hospital, Málaga, Spain.
ORCID-Profile: Teresa Valdés Delgado
Zitieren
APA
Argüelles-Arias, F., Rodriguez González, F. J., González Antuña, J., Castro Laria, L., Gutiérrez Martinez, F., Alcaín Martinez, G., Maldonado Pérez, B., Camargo Camero, R., Martos Van Dussen, J. V., Fernández Castañer, A., & Valdés Delgado, T. (2025). Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae152
Vancouver
Argüelles-Arias F, Rodriguez González FJ, González Antuña J, Castro Laria L, Gutiérrez Martinez F, Alcaín Martinez G, et al. Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae152
BibTeX
@article{ArgellesArias2025,
author = {Argüelles-Arias, Federico and Rodriguez González, F Javier and González Antuña, Jaime and Castro Laria, Luisa and Gutiérrez Martinez, Fernando and Alcaín Martinez, Guillermo and Maldonado Pérez, Belén and Camargo Camero, Raquel and Martos Van Dussen, J Victor and Fernández Castañer, Alejandra and Valdés Delgado, Teresa},
title = {Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izae152}
}
EUVIMED